About biomea fusion inc - BMEA
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
BMEA At a Glance
Biomea Fusion, Inc.
1599 Industrial Road
San Carlos, California 94070
| Phone | 1-650-980-9099 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -61,797,000.00 | |
| Sector | Health Technology | Employees | 41 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BMEA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.034 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.132 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.151 |
BMEA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,507,243.902 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BMEA Liquidity
| Current Ratio | 5.229 |
| Quick Ratio | 5.229 |
| Cash Ratio | 5.028 |
BMEA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -89.231 |
| Return on Equity | -152.35 |
| Return on Total Capital | -198.443 |
| Return on Invested Capital | -140.536 |
BMEA Capital Structure
| Total Debt to Total Equity | 5.377 |
| Total Debt to Total Capital | 5.103 |
| Total Debt to Total Assets | 2.713 |
| Long-Term Debt to Equity | 0.433 |
| Long-Term Debt to Total Capital | 0.411 |